Wedbush Increases Keros Therapeutics (NASDAQ:KROS) Price Target to $16.00

Keros Therapeutics (NASDAQ:KROS) had its price target hoisted by equities research analysts at Wedbush from $15.00 to $16.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm currently has a “neutral” rating on the stock. Wedbush’s price target would indicate a potential downside of 1.23% from the stock’s current price.

Several other research firms also recently issued reports on KROS. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Keros Therapeutics in a report on Wednesday, October 8th. HC Wainwright decreased their price target on Keros Therapeutics from $25.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Finally, Wells Fargo & Company began coverage on Keros Therapeutics in a report on Monday, October 20th. They set an “overweight” rating and a $26.00 price objective for the company. Six investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $30.11.

Keros Therapeutics Stock Performance

Shares of Keros Therapeutics stock opened at $16.20 on Thursday. The firm’s 50-day simple moving average is $15.50 and its 200-day simple moving average is $14.63. Keros Therapeutics has a twelve month low of $9.12 and a twelve month high of $72.37. The firm has a market cap of $493.61 million, a P/E ratio of 10.52, a price-to-earnings-growth ratio of 2.08 and a beta of 1.12.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.11) by $0.93. The firm had revenue of $14.26 million during the quarter, compared to analyst estimates of $4.22 million. Keros Therapeutics had a net margin of 26.12% and a return on equity of 9.63%. The company’s quarterly revenue was up 3585.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.41) earnings per share. On average, equities analysts forecast that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Pontifax Management 4 G.P. (20 sold 4,787,331 shares of the business’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total transaction of $84,975,125.25. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder Adar1 Capital Management, Llc sold 5,389,264 shares of the firm’s stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total transaction of $95,659,436.00. Additional details regarding this sale are available in the official SEC disclosure. 20.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. CWM LLC grew its stake in shares of Keros Therapeutics by 10,157.7% in the first quarter. CWM LLC now owns 2,667 shares of the company’s stock valued at $27,000 after acquiring an additional 2,641 shares in the last quarter. Farther Finance Advisors LLC bought a new stake in shares of Keros Therapeutics during the 3rd quarter worth approximately $47,000. Tower Research Capital LLC TRC grew its stake in shares of Keros Therapeutics by 149.2% in the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock worth $42,000 after purchasing an additional 1,888 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Keros Therapeutics in the third quarter valued at $103,000. Finally, Police & Firemen s Retirement System of New Jersey raised its position in Keros Therapeutics by 29.7% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 8,257 shares of the company’s stock worth $110,000 after purchasing an additional 1,892 shares during the last quarter. Institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.